

## References

1. van Bommel EF. Retroperitoneal fibrosis. *Neth J Med.* 2002;60:231-42. [PMID: 12365466]
2. Baker LR. Auto-allergic periaortitis (idiopathic retroperitoneal fibrosis). *BJU Int.* 2003;92:663-5. [PMID: 14616440]
3. Parums DV. The spectrum of chronic periaortitis. *Histopathology.* 1990;16:423-31. [PMID: 2193863]
4. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. *Ann Intern Med.* 2004;141:764-70. [PMID: 15545676]
5. Grainger DI, Schofield PM. Tamoxifen for the prevention of myocardial infarction in humans: preclinical and early clinical evidence. *Circulation.* 2005;112:3018-24. [PMID: 16275887]

## CORRECTIONS

### Correction: A Prognostic Index for Systemic AIDS-Related Non-Hodgkin Lymphoma Treated in the Era of Highly Active Antiretroviral Therapy

In a recent article regarding a prognostic index for systemic AIDS-related non-Hodgkin lymphoma (1), the hazard ratios shown in Table 1 should read 1.00 for men and 1.20 for women. The bootstrap hazard ratios in Table 2 should have been calculated as  $\exp(\text{mean (coefficient)})$ ; the corrected Table is shown. The authors of the article acknowledged Drs. Harrell and Steyerberg without their written permission to do so; the Editors regret that we did not note the absence of appropriate permission before publication.

## Reference

1. Bower M, Gazzard B, Mandalia S, Newsom-Davis T, Thirlwell C, Dhillon T, et al. A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. *Ann Intern Med.* 2005;143:265-73. [PMID: 16103470]

**Table. Multivariable Cox Proportional Hazards Regression Model Showing Significant Independent Predictors of Death after Diagnosis of AIDS-Related Non-Hodgkin Lymphoma in the Era of Highly Active Antiretroviral Therapy\***

Variable	Hazard Ratio (95% CI) <sup>†</sup>	P Value	Hazard Ratio Bootstrap Estimate (95% CI)
<b>CD4 cell count</b>			
<100 × 10 <sup>6</sup> cells/L	2.08 (1.20–3.60)	0.009	2.35 (1.15–4.79)
≥100 × 10 <sup>6</sup> cells/L	1		1
<b>International Prognostic Index risk group</b>			
High	4.88 (1.544–15.43)	0.007	5.31 (1.24–22.80)
High-intermediate	2.74 (0.94–8.04)	0.066	2.90 (0.82–10.21)
Low-intermediate	1.73 (0.57–5.21)	>0.2	1.88 (0.56–6.26)
Low	1		1

\* The model includes the International Prognostic Index risk group and excludes the list of variables that were significant in the univariate model. The validity of the prognostic score was calculated internally on the 111 patients in whom AIDS-related non-Hodgkin lymphoma was diagnosed in the era of highly active antiretroviral therapy.

<sup>†</sup> Adjusted for age, sex, type B symptoms, bone marrow and meningeal disease at diagnosis, Burkitt lymphoma, and other variables in the model.

### Correction: Summaries for Patients: Exenatide or Insulin Glargine for Suboptimally Controlled Type 2 Diabetes?

In a recent Summary for Patients (1), the third sentence under the heading “What were the limitations of the study?” should have read as follows: “Only 21.6% and 8.6% of the patients taking insulin and exenatide, respectively, achieved target fasting glucose levels of 100 mg/dL.”

## Reference

1. Summaries for patients. Exenatide or insulin glargine for suboptimally controlled diabetes? *Ann Intern Med.* 2005;143:130. [PMID: 16230718]